Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer

Standard

Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. / Schneeweiss, Andreas; Bauerfeind, Ingo; Fehm, Tanja; Janni, Wolfgang; Thomssen, Christoph; Witzel, Isabell; Wöckel, Achim; Müller, Volkmar.

In: BREAST CARE, Vol. 15, No. 6, 12.2020, p. 608-618.

Research output: SCORING: Contribution to journalSCORING: Review articleResearch

Harvard

Schneeweiss, A, Bauerfeind, I, Fehm, T, Janni, W, Thomssen, C, Witzel, I, Wöckel, A & Müller, V 2020, 'Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer', BREAST CARE, vol. 15, no. 6, pp. 608-618. https://doi.org/10.1159/000511925

APA

Schneeweiss, A., Bauerfeind, I., Fehm, T., Janni, W., Thomssen, C., Witzel, I., Wöckel, A., & Müller, V. (2020). Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. BREAST CARE, 15(6), 608-618. https://doi.org/10.1159/000511925

Vancouver

Schneeweiss A, Bauerfeind I, Fehm T, Janni W, Thomssen C, Witzel I et al. Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. BREAST CARE. 2020 Dec;15(6):608-618. https://doi.org/10.1159/000511925

Bibtex

@article{fe504386b5b3452f9cdbe195cbef49a4,
title = "Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer",
abstract = "Background: In order to offer optimal treatment approaches based on available evidence, the Commission Breast of the Working Group Gynecologic Oncology (AGO) of the German Cancer Society developed therapy algorithms for eight complex treatment situations in primary and advanced breast cancer.Summary: Therapy algorithms for the following complex treatment situations are outlined in this paper: (neo)adjuvant therapy of human epidermal growth factor receptor 2 (HER2)-positive breast cancer; axillary surgery and neoadjuvant chemotherapy; adjuvant endocrine therapy in premenopausal patients; adjuvant endocrine therapy in postmenopausal patients; hormone receptor (HR)-positive/HER2-negative metastatic breast cancer: strategies; HR-positive/HER2-negative metastatic breast cancer: endocrine-based first-line treatment; HER2-positive metastatic breast cancer: first to third-line; metastatic triple-negative breast cancer.Key Messages: The therapy options shown in these algorithms are based on the current AGO recommendations updated in January 2020 but cannot represent all evidence-based treatment options. Prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. Therefore, in individual cases, other evidence-based treatment options not listed here may also be appropriate and justified.",
author = "Andreas Schneeweiss and Ingo Bauerfeind and Tanja Fehm and Wolfgang Janni and Christoph Thomssen and Isabell Witzel and Achim W{\"o}ckel and Volkmar M{\"u}ller",
note = "Copyright {\textcopyright} 2020 by S. Karger AG, Basel.",
year = "2020",
month = dec,
doi = "10.1159/000511925",
language = "English",
volume = "15",
pages = "608--618",
journal = "BREAST CARE",
issn = "1661-3791",
publisher = "S. Karger AG",
number = "6",

}

RIS

TY - JOUR

T1 - Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer

AU - Schneeweiss, Andreas

AU - Bauerfeind, Ingo

AU - Fehm, Tanja

AU - Janni, Wolfgang

AU - Thomssen, Christoph

AU - Witzel, Isabell

AU - Wöckel, Achim

AU - Müller, Volkmar

N1 - Copyright © 2020 by S. Karger AG, Basel.

PY - 2020/12

Y1 - 2020/12

N2 - Background: In order to offer optimal treatment approaches based on available evidence, the Commission Breast of the Working Group Gynecologic Oncology (AGO) of the German Cancer Society developed therapy algorithms for eight complex treatment situations in primary and advanced breast cancer.Summary: Therapy algorithms for the following complex treatment situations are outlined in this paper: (neo)adjuvant therapy of human epidermal growth factor receptor 2 (HER2)-positive breast cancer; axillary surgery and neoadjuvant chemotherapy; adjuvant endocrine therapy in premenopausal patients; adjuvant endocrine therapy in postmenopausal patients; hormone receptor (HR)-positive/HER2-negative metastatic breast cancer: strategies; HR-positive/HER2-negative metastatic breast cancer: endocrine-based first-line treatment; HER2-positive metastatic breast cancer: first to third-line; metastatic triple-negative breast cancer.Key Messages: The therapy options shown in these algorithms are based on the current AGO recommendations updated in January 2020 but cannot represent all evidence-based treatment options. Prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. Therefore, in individual cases, other evidence-based treatment options not listed here may also be appropriate and justified.

AB - Background: In order to offer optimal treatment approaches based on available evidence, the Commission Breast of the Working Group Gynecologic Oncology (AGO) of the German Cancer Society developed therapy algorithms for eight complex treatment situations in primary and advanced breast cancer.Summary: Therapy algorithms for the following complex treatment situations are outlined in this paper: (neo)adjuvant therapy of human epidermal growth factor receptor 2 (HER2)-positive breast cancer; axillary surgery and neoadjuvant chemotherapy; adjuvant endocrine therapy in premenopausal patients; adjuvant endocrine therapy in postmenopausal patients; hormone receptor (HR)-positive/HER2-negative metastatic breast cancer: strategies; HR-positive/HER2-negative metastatic breast cancer: endocrine-based first-line treatment; HER2-positive metastatic breast cancer: first to third-line; metastatic triple-negative breast cancer.Key Messages: The therapy options shown in these algorithms are based on the current AGO recommendations updated in January 2020 but cannot represent all evidence-based treatment options. Prior therapies, performance status, comorbidities, patient preference, etc. must be taken into account for the actual treatment choice. Therefore, in individual cases, other evidence-based treatment options not listed here may also be appropriate and justified.

U2 - 10.1159/000511925

DO - 10.1159/000511925

M3 - SCORING: Review article

C2 - 33447235

VL - 15

SP - 608

EP - 618

JO - BREAST CARE

JF - BREAST CARE

SN - 1661-3791

IS - 6

ER -